NCT04682847View on ClinicalTrials.gov

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

Active, not recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Liver NeoplasmsHepatic CirrhosisHepatic CarcinomaLiver CancerLiver MetastasesLiver CarcinomaHepatocellular CarcinomaHepatocellular CancerHepatic Atrophy
Interventions
DRUG

Ferumoxytol injection

This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.

Trial Locations (1)

15212

Allegheny General Hospital, Pittsburgh

All Listed Sponsors
lead

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

OTHER